O-GlcNAc transferase - an auxiliary factor or a full-blown oncogene? by Itkonen, HM, Loda, M, Mills, IG

Inhibition of CDK9 activity compromises global splicing in prostate cancer cells by Hu, Q, Poulose, N, Girmay, S, Helevä, A, Doultsinos, D, Gondane, A, Steele, RE, Liu, X, Loda, M, Liu, S, Tang, D, Mills, IG, Itkonen, HM

Inhibition of O-GlcNAc transferase renders prostate cancer cells dependent on CDK9 by Itkonen, HM, Poulose, N, Steele, RE, Martin, SES, Levine, ZG, Duveau, DY, Carelli, R, Singh, R, Urbanucci, A, Loda, M, Thomas, CJ, Mills, IG, Walker, S

Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration by Wang, Z, Cao, S, Morris, J, Ahn, J, Liu, R, Tyekucheva, S, Gao, F, Li, B, Lu, W, Tang, X, Wistuba, I, Bowden, M, Mucci, L, Loda, M, Parmigiani, G, Holmes, C, Wang, W

Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. by Flavin, R, Smyth, P, Finn, S, Laios, A, O'Toole, SA, Barrett, C, Ring, M, Denning, K, Li, J, Aherne, S, Aziz, N, Alhadi, A, Sheppard, B, Loda, M, Martin, C, Sheils, O, O'Leary, J

Ductal adenocarcinoma of the prostate: A systematic review and meta‐analysis of incidence, presentation, prognosis, and management by Ranasinha, N, Omer, A, Philippou, Y, Harriss, E, Davies, L, Chow, K, Chetta, PM, Erickson, A, Rajakumar, T, Mills, IG, Bryant, RJ, Hamdy, FC, Murphy, DG, Loda, M, Hovens, CM, Corcoran, NM, Verrill, C, Lamb, AD

MIR-29B expression is associated with disease-free survival in ovarian serous carcinoma patients by Flavin, R, Smyth, P, Barrett, C, Russell, S, Wen, H, Wei, J, Laios, A, OToole, S, Ring, M, Denning, K, Li, J, Aherne, S, Sammarae, D, Aziz, N, Alhadi, A, Finn, S, Loda, M, Sheppard, B, Sheils, O, OLeary, J

miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. by Flavin, R, Smyth, P, Barrett, C, Russell, S, Wen, H, Wei, J, Laios, A, O'Toole, S, Ring, M, Denning, K, Li, J, Aherne, S, Sammarae, D, Aziz, N, Alhadi, A, Finn, S, Loda, M, B, S, Sheils, O, O'Leary, J

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures by Figiel, S, Yin, W, Doultsinos, D, Erickson, A, Poulose, N, Singh, R, Magnussen, A, Anbarasan, T, Teague, R, He, M, Lundeberg, J, Loda, M, Verrill, C, Colling, R, Gill, PS, Bryant, RJ, Hamdy, FC, Woodcock, DJ, Mills, IG, Cussenot, O, Lamb, AD

Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. by Grisanzio, C, Werner, L, Takeda, D, Awoyemi, B, Pomerantz, M, Yamada, H, Sooriakumaran, P, Robinson, B, Leung, R, Schinzel, A, Mills, I, Ross-Adams, H, Neal, D, Kido, M, Yamamoto, T, Petrozziello, G, Stack, E, Lis, R, Kantoff, P, Loda, M, Sartor, O, Egawa, S, Tewari, A, Hahn, W, Freedman, M

ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer by Centenera, MM, Scott, JS, Machiels, J, Nassar, ZD, Miller, DC, Zininos, I, Dehairs, J, Burvenich, IJG, Zadra, G, Chetta, P, Bango, C, Evergren, E, Ryan, NK, Gillis, JL, Mah, CY, Tieu, T, Hanson, AR, Carelli, R, Bloch, K, Panagopoulos, V, Waelkens, E, Derua, R, Williams, ED, Evdokioou, A, Cifuentes-Rius, A, Voelcker, NH, Mills, IG, Tilley, WD, Scott, AM, Loda, M, Selth, LA, Swinnen, JV, Butler, LM